The Quantellect read.As of Nov 20, 2026, 9 active firms cover Kura Oncology Inc: 9 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $15.00 to $40.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $27.00 sits 268% above the current $7.34. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.69 next quarter toward $-2.39 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy00%
Buy9100%
Neutral00%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 20, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$27.00
+267.6% upside
Average target across 9 active firms as of Nov 20, 2026 vs $7.35 current
Highest Target$40.00
Average Target$27.00
Lowest Target$15.00
Detailed analyst forecasts for KURA
Showing 1–8 of 8 named analysts shown · 9 active firms in the rating projection
As of Nov 20, 2026, 9 of 9 active firms rate KURA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
KURA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.69
Range $-0.80 – $-0.60 · 3 analysts
Next period, 3 analysts expect Kura Oncology Inc to earn $-0.69 a share (range $-0.80 – $-0.60), versus — a year earlier. Full-year consensus is $-3.21, growing to $-2.39 the year after.
REVENUE · NEXT QUARTER
$39.4M
Range $30.0M – $47.0M · 3 analysts
Revenue is expected to reach $39.4M (range $30.0M – $47.0M). Full-year consensus is $94.0M, rising to $200.4M next year.
Top analysts covering Kura Oncology Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KURA.
#1
David Nierengarten
Wedbush · Rank #24
Buy
$36.00+390.1% to target
Overall win rate
48%
+ Follow
#2
Peter Lawson
Barclays · Rank #89
Buy
$11.00+49.8% to target
Overall win rate
45%
+ Follow
#3
Roger Song
Jefferies · Rank #122
Buy
$28.00+281.2% to target
Overall win rate
43%
+ Follow
#4
George Farmer
Scotiabank · Rank #311
Neutral
$8.00+8.9% to target
Overall win rate
44%
+ Follow
#5
Li Watsek
Cantor Fitzgerald · Rank #357
Buy
No targeton KURA
Overall win rate
38%
+ Follow
KURA stock forecast FAQ
What is KURA's average 12-month price target?+
The 9 active firms with a live target average $27.00 for Kura Oncology Inc over the next 12 months, ranging from a $40.00 high to a $15.00 low, as of Nov 20, 2026.
Is KURA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 20, 2026, 9 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for KURA?+
The Street-high target is $40.00 (HC Wainwright & Co.), and the Street-low is $15.00 (UBS). The average of all 9 active-firm targets is $27.00.
How many active Wall Street firms cover KURA?+
9 active firms have a recognized rating on Kura Oncology Inc as of Nov 20, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering KURA?+
Among analysts who currently cover KURA, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $36.00 target.
What is Kura Oncology Inc's projected EPS for next quarter?+
The consensus estimate is $-0.69 per share (range $-0.80 – $-0.60) across 3 analysts. Full-year EPS is projected at $-3.21, rising to $-2.39 the following year.
How much revenue is Kura Oncology Inc expected to report next quarter?+
Consensus revenue is $39.4M (range $30.0M – $47.0M). Full-year revenue is projected at $94.0M, growing to $200.4M next year.
Have analysts been upgrading or downgrading KURA lately?+
As of Nov 20, 2026, 9 of 9 active firms rate KURA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KURA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.